{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:51:54Z","timestamp":1785167514451,"version":"3.55.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00560","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T09:43:14Z","timestamp":1561542194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer"],"prefix":"10.3389","volume":"9","author":[{"given":"Charles A.","family":"Kunos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Capala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise C.","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,26]]},"reference":[{"key":"B1","first-page":"1","volume-title":"Cancer Facts & Figures 2019.","year":"2019"},{"key":"B2","volume-title":"GLOBOCAN 2012v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11","author":"Ferlay","year":"2013"},{"key":"B3","volume-title":"Surveillance, Epidemiology, and End Results Program","year":"2019"},{"key":"B4","unstructured":"NCI Experimental Therapeutics Clinical Trials Network (ETCTN).2019"},{"key":"B5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ygyno.2016.09.026","article-title":"The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies","volume":"143","author":"Mishkin","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7834","DOI":"10.1074\/jbc.M512894200","article-title":"Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells","volume":"281","author":"H\u00e5kansson","year":"2006","journal-title":"J Biol Chem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"001","DOI":"10.4172\/2161-0932.S4-001","article-title":"Molecular strategies of deoxynucleotide triphosphate supply inhibition used in the treatment of gynecologic malignancies","author":"Kunos","year":"2011","journal-title":"Gynecol Obstet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"14324","DOI":"10.1073\/pnas.0706803104","article-title":"Enhanced subunit interactions with gemcitabine-5\u2032-diphosphate inhibit ribonucleotide reductases","volume":"104","author":"Wang","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B9","first-page":"4389","article-title":"Effect of methotrexate and 5-fluorodeoxyuridine on ribonucleotide reductase activity in mammalian cells","volume":"37","author":"Elford","year":"1977","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1098\/rstb.2006.1874","article-title":"Proton-coupled electron transfer: the mechanistic underpinning for radical transport and catalysis in biology","volume":"361","author":"Reece","year":"2006","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"17747","DOI":"10.1074\/jbc.M000799200","article-title":"Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks","volume":"275","author":"Chabes","year":"2000","journal-title":"J Biol Chem"},{"key":"B12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/35003506","article-title":"A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage","volume":"404","author":"Tanaka","year":"2000","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11569","DOI":"10.1021\/bi00094a013","article-title":"Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea","volume":"32","author":"Nyholm","year":"1993","journal-title":"Biochemistry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.jinorgbio.2011.07.003","article-title":"Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study","volume":"105","author":"Popovi\u0107-Bijeli\u0107","year":"2011","journal-title":"J Inorg Biochem"},{"key":"B15","first-page":"2245","article-title":"Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells","volume":"58","author":"Kuo","year":"1998","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1667\/RR1858.1","article-title":"Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein","volume":"172","author":"Kunos","year":"2009","journal-title":"Radiat Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1667\/RR2273.1","article-title":"Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers","volume":"174","author":"Kunos","year":"2010","journal-title":"Radiat Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1667\/RR2556.1","article-title":"Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers","volume":"176","author":"Kunos","year":"2011","journal-title":"Radiat Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1097\/IGC.0b013e31821dc8b5","article-title":"18F-fluoro-2-deoxy-D-glucose positron emission tomography standard uptake value ratio as an indicator of cervical cancer chemoradiation therapeutic response","volume":"21","author":"Kunos","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1097\/IGC.0b013e318270577f","article-title":"Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers","volume":"22","author":"Kunos","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/IGC.0b013e31828b4eb5","article-title":"Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis","volume":"23","author":"Kunos","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.1999.17.5.1339","article-title":"Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study","volume":"17","author":"Whitney","year":"1999","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1200\/JCO.2004.07.197","article-title":"Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90\u201301","volume":"22","author":"Eifel","year":"2004","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1200\/JCO.2006.09.4532","article-title":"Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Rose","year":"2007","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-09-2469","article-title":"Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer","volume":"16","author":"Kunos","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ygyno.2013.04.019","article-title":"Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers","volume":"130","author":"Kunos","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","year":"2017","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ijgo.2014.02.003","article-title":"FIGO staging for carcinoma of the vulva, cervix, and corpus uteri","volume":"125","year":"2014","journal-title":"Int J Gynaecol Obstet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ijgo.12611","article-title":"Cancer of the cervix uteri","volume":"143","author":"Bhatla","year":"2018","journal-title":"In J Gynaecol Obstet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ygyno.2018.10.026","article-title":"Validation of the 2018 FIGO cervical cancer staging system","volume":"152","author":"Matsuo","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0090-8258(03)00173-2","article-title":"Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group","volume":"89","author":"Keys","year":"2003","journal-title":"Gynecol Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","article-title":"Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma","volume":"340","author":"Keys","year":"1999","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(97)02250-2","article-title":"Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer","volume":"350","author":"Landoni","year":"1997","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2214\/ajr.123.1.91","article-title":"Indications for adjunctive conservative extrafascial hysterectomy in selected cases of carcinoma of the uterine cervix","volume":"123","author":"Nelson","year":"1975","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/1097-0142(197607)38:1<596::AID-CNCR2820380184>3.0.CO;2-C","article-title":"Clinical studies with adjunctive surgery and irradiation therapy in the treatment of carcinoma of the cervix","volume":"38","author":"Rutledge","year":"1976","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/0090-8258(89)90070-X","article-title":"A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study","volume":"35","author":"Delgado","year":"1989","journal-title":"Gynecol Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"503.e1","DOI":"10.1016\/j.ajog.2007.08.003","article-title":"Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial","volume":"197","author":"Stehman","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/EDBK_200199","article-title":"National cancer institute programmatic collaboration for investigational radiopharmaceuticals","volume":"23","author":"Kunos","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fonc.2019.00097","article-title":"Radiopharmaceuticals for relapsed or refractory leukemias","volume":"9","author":"Kunos","year":"2019","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fonc.2018.00102","article-title":"Leveraging national cancer institute programmatic collaboration for uterine cervix cancer patient accrual in Puerto Rico","volume":"8","author":"Kunos","year":"2018","journal-title":"Front Oncol"},{"key":"B41","unstructured":"Appalachian Regional Commission.2018"},{"key":"B42","unstructured":"29991743Cervical Cancer.2019"},{"key":"B43","volume-title":"ICRU Report 16: Linear Energy Transfer","year":"1970"},{"key":"B44","article-title":"In vitro and in vivo activity of a HER2-targeted thorium-227 conjugate (HER2-TTC) in HER2 low expressing and T-DM1\/trastuzumab resistant preclinical mouse models","volume-title":"2018 NCI-AACR-EORTC Molecular Targets and Cancer Therapeutics Symposium.","author":"Karlsson","year":"2018"},{"key":"B45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1471-2407-4-59","article-title":"HER2 expression in cervical cancer as a potential therapeutic target","volume":"4","author":"Chavez-Blanco","year":"2004","journal-title":"BMC Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000195539","article-title":"Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer","volume":"76","author":"P\u00e9rez-Regadera","year":"2009","journal-title":"Oncology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"36219","DOI":"10.18632\/oncotarget.5283","article-title":"HER2 as a novel therapeutic target for cervical cancer","volume":"6","author":"Oh","year":"2015","journal-title":"Oncotarget"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","article-title":"Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1200\/JCO.2009.26.7278","article-title":"Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors","volume":"28","author":"Yap","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00560\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T09:43:22Z","timestamp":1561542202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00560\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,26]]},"references-count":50,"alternative-id":["10.3389\/fonc.2019.00560"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00560","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,26]]},"article-number":"560"}}